Astrazeneca (AZN) Non-Current Deferred Tax Liability (2009 - 2026)

Astrazeneca's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at -$3.5 billion for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 2.31% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at -$3.5 billion (up 2.31% YoY), while the FY2025 annual figure was -$3.5 billion, down 205.9% from the prior year.
• Non-Current Deferred Tax Liability was -$3.5 billion for Q1 2026 at Astrazeneca, up from -$3.5 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.3 billion in Q4 2024 to a low of -$5.6 billion in Q1 2022.
• Historically, Non-Current Deferred Tax Liability has averaged -$2.4 billion across 5 years, with a median of -$3.5 billion in 2026.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability surged 50.32% in 2023, then sank 205.9% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.9 billion in 2022, then fell by 3.4% to $2.8 billion in 2023, then advanced by 16.21% to $3.3 billion in 2024, then tumbled by 205.9% to -$3.5 billion in 2025, then gained by 0.83% to -$3.5 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at -$3.5 billion (Q1 2026), -$3.5 billion (Q4 2025), and -$3.6 billion (Q3 2025), per Business Quant data.